Genomic DNA from *Brucella abortus*, Strain RB51

Catalog No. NR-2553

This reagent is the property of the U.S. Government.

For research use only. Not for human use.

Contributor:

Centers for Disease Control and Prevention, Atlanta, Georgia

Product Description:

Genomic DNA was isolated from a preparation of *Brucella abortus (B. abortus)*, strain RB51.

B. abortus is a non-motile, aerobic, gram-negative coccobacillus which displays a moderate degree of human virulence. Very little is known about the genetics of *Brucella* virulence, largely due to a lack of classical virulence factors. A type IV secretion system has been identified as essential for intracellular survival and multiplication of *Brucella*.[1]

B. abortus, strain RB51 is an attenuated, stable rough mutant derived from the virulent strain 2308.[2,3] *B. abortus*, strain RB51 is the official vaccine for the U.S. bovine eradication program, and is also being used in several other countries to prevent and control animal brucellosis.

NR-2553 has been qualified for PCR applications by amplification of ~ 1430 bp of the 16S ribosomal RNA gene.

Material Provided:

Each vial contains approximately 2 µg bacterial genomic DNA, lyophilized from 0.05 mL containing TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH ~ 8.0). The vial should be centrifuged prior to opening.

Packaging/Storage:

NR-2553 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen and should be stored at 4°C or colder immediately upon arrival. For optimal long-term storage, freezing the material at -20°C or colder is recommended. Freeze-thaw cycles should be minimized.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Genomic DNA from *Brucella abortus*, Strain RB51, NR-2553."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 4th ed. Washington, DC: U.S. Government Printing Office, 1999. HHS Publication No. (CDC) 93-8395. This text is available online at www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Boschiroli, M. L., et al. "Type IV Secretion and *Brucella* Virulence." Vet. Microbiol. 90 (2002): 341–348. PubMed: 12414154.
2. Schurig, G. G., et al. "Biological Properties of RB51; a Stable Rough Strain of *Brucella abortus*." Vet. Microbiol. 28 (1991): 171–188. PubMed: 1908158.
3. Vemulapalli, R., et al. "*Brucella abortus* RB51: Enhancing Vaccine Efficacy and Developing Multivalent Vaccines." Vet. Microbiol. 90 (2002): 521–532. PubMed: 12414168.
4. Halling, S. M., et al. "Completion of the Genome Sequence of *Brucella abortus* and Comparison to the Highly Similar Genomes of *Brucella melitensis* and

Biodefense and Emerging Infections Research Resources Repository
P.O. Box 4137
Manassas, VA 20108-4137 USA
www.beiresources.org
800-359-7370
Fax: 703-365-2898
E-mail: contact@beiresources.org

Brucella suis." J. Bacteriol. 187 (2005): 2715–2726. PubMed: 15805518.
5. Chain, P. S. et al. "Whole-Genome Analyses of Speciation Events in Pathogenic Brucellae." Infect. Immun. 73 (2005): 8353–8361. PubMed: 16299333.
6. Ratushna, V. G., et al. "Molecular Targets for Rapid Identification of *Brucella* spp." BMC Microbiol. 6 (2006): 13. PubMed: 16504063.
7. Ciocchini, A. E., et al. "Identification of Active Site Residues of the Inverting Glycosyltransferase Cgs Required for the Synthesis of Cyclic β-1,2-Glucan, A *Brucella abortus* Virulence Factor." Glycobiology 16 (2006): 679–691. PubMed: 16603625.

Biodefense and Emerging Infections Research Resources Repository
P.O. Box 4137
Manassas, VA 20108-4137 USA
www.beiresources.org

800-359-7370
Fax: 703-365-2898
E-mail: contact@beiresources.org